PharmaCell to make autologous cell therapies for Lion Biotech

By Flora Southey contact

- Last updated on GMT


Related tags: Cancer

Dutch contract manufacturer PharmaCell B.V has signed a three-year Manufacturing Services Agreement to make cancer cell therapies for Lion Biotechnologies.

US-based oncology firm Lion told BioPharma-Reporter that a number of vendors were evaluated in Europe, and that PharmaCell’s location and proximity to major cities was an advantage.

PharmaCell’s clinical and commercial capabilities also influenced the decision: “From a technical perspective, having a site which has offered a commercial product was a strong selection factor,” ​a spokesperson told us.

Cancer candidate

Lion is developing clinical-stage cancer immunotherapies founded on tumour-infiltrating lymphocyte technology (TIL). Its leading candidate is currently being investigated for the treatment of refractory metastic melanomas, metastic squamous cell carcinomas and metastic cervical carcinomas.

PharmaCell will manufacture Lion’s autologous cell therapy products in its clinical and commercial facility in Geleen, the Netherlands.

“This collaboration will result in a substantial increase in our worldwide TIL manufacturing capacity, as we expand our clinical trial program in Europe,” ​Lion president and CEO Maria Fardis said in a statement.

Lion said it has already started transferring manufacturing technologies to the PharmaCell facility.

Lion did not disclose when it expects production to be completed, which will depend on regulatory interactions and clinical site engagement. 

Related topics: Upstream Processing, Bio-Outsourcing

Related news

Show more

Related products

show more

Rapid Biosafety Testing Enables the Future of Manufacturing

Rapid Biosafety Testing Enables the Future of Manufacturing

Viral Safety for mAb: Prevent, Detect, Remove | 05-Aug-2020 | Technical / White Paper

Traditional methods for adventitious agent testing rely on biological amplification and detection, which can take several weeks. This time-consuming approach...

Related suppliers

Follow us


View more